{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:37:15Z","timestamp":1740123435864,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The purpose of the present study was to compare the long-term effectiveness and safety of newly initiated anticoagulation with edoxaban (EDO) versus uninterrupted vitamin K antagonist (VKA) therapy in patients with atrial fibrillation (AF) scheduled for transesophageal echocardiogram (TEE)-guided direct electrical current cardioversion (DCC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A propensity score-matched cohort observational study was performed comparing the safety and effectiveness of edoxaban versus well-controlled VKA therapy among a cohort of consecutive non-valvular AF patients scheduled for DCC. The primary safety outcome was major bleeding. The primary efficacy outcome was the composite of stroke, transient ischemic attack (TIA), and systemic embolism (SE).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Findings<\/jats:title>\n                <jats:p>A total of 130 AF patients receiving edoxaban 60-mg (EDO) treatment were compared with the same number of VKA recipients. The cumulative incidence of major bleedings was 1.54% in the EDO group and 3.08% in the VKA group (<jats:italic>P\u2009=<\/jats:italic>\u00a00.4)<jats:italic>.<\/jats:italic> The cumulative incidence of thromboembolic events was 1.54% in the EDO group and 2.31% in the VKA group (<jats:italic>P\u2009=<\/jats:italic>\u00a00.9)<jats:italic>.<\/jats:italic> A non-significant trend in improved adherence was observed between the EDO and VKA groups with a total anticoagulant therapy discontinuation rate of 4.62% (6\/130) vs 6.15% (8\/130), respectively (<jats:italic>P\u2009=<\/jats:italic>\u00a00.06).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Implications<\/jats:title>\n                <jats:p>Our study provides the evidence of a safe and effective use of edoxaban in this clinical setting, justified by no significant difference in major bleedings and thromboembolic events between edoxaban and well-controlled VKA treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-020-07078-7","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T08:03:53Z","timestamp":1600416233000},"page":"1003-1007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score\u2013Matched Study"],"prefix":"10.1007","volume":"35","author":[{"given":"Anna","family":"Rago","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5654-4686","authenticated-orcid":false,"given":"Andrea Antonio","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Attena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Golino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"issue":"19","key":"7078_CR1","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"AJ Camm","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369\u2013429.","journal-title":"Eur Heart J"},{"issue":"23","key":"7078_CR2","first-page":"e199","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. AHA\/ACC\/ HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199\u2013267.","journal-title":"Circulation"},{"issue":"20","key":"7078_CR3","first-page":"3961","volume":"19","author":"V Russo","year":"2015","unstructured":"Russo V, Bianchi V, Cavallaro C, et al. Efficacy and safety of dabigatran in a \u201creal-life\u201d population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry. Eur Rev Med Pharmacol Sci. 2015;19(20):3961\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"7078_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/2042098616673990","volume":"8","author":"V Russo","year":"2017","unstructured":"Russo V, Rago A, Proietti R, di Meo F, Antonio Papa A, Calabr\u00f2 P, et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf. 2017;8(2):67\u201375.","journal-title":"Ther Adv Drug Saf"},{"issue":"11","key":"7078_CR5","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2459\/JCM.0000000000000548","volume":"18","author":"V Russo","year":"2017","unstructured":"Russo V, Rago A, D\u2019Onofrio A, et al. The clinical performance of dabigatran in the Italian real-life experience. J Cardiovasc Med (Hagerstown). 2017;18(11):922\u20133.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"7078_CR6","first-page":"370","volume":"44","author":"V Russo","year":"2017","unstructured":"Russo V, Rago A, Papa AA, Meo F, Attena E, Golino P, et al. Use of non\u2013vitamin K antagonist oral anticoagulants in atrial fibrillation patients with malignancy: clinical practice experience in a single institution and literature review. SeminThrombHemost. 2017;44:370\u20136.","journal-title":"SeminThrombHemost"},{"key":"7078_CR7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1055\/s-0037-1615261","volume":"44","author":"V Russo","year":"2018","unstructured":"Russo V, Attena E, Mazzone C, Esposito F, Parisi V, Bancone C, et al. Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves\/prior surgical valve repair: a multicenter clinical practice experience. Semin Thromb Hemost. 2018;44:364\u20139.","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"7078_CR8","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/j.clinthera.2019.10.008","volume":"41","author":"V Russo","year":"2019","unstructured":"Russo V, Carbone A, Attena E, Rago A, Mazzone C, Proietti R, et al. Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves. Clin Ther. 2019;41(12):2549\u201357.","journal-title":"Clin Ther"},{"issue":"8","key":"7078_CR9","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.clinthera.2019.04.041","volume":"41","author":"V Russo","year":"2019","unstructured":"Russo V, Attena E, Mazzone C, Melillo E, Rago A, Galasso G, et al. Real-life performance of edoxaban in elderly patients with atrial fibrillation: a multicenter propensity score-matched cohort study. Clin Ther. 2019;41(8):1598\u2013604.","journal-title":"Clin Ther"},{"issue":"32","key":"7078_CR10","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1093\/eurheartj\/ehy148","volume":"39","author":"MD Ezekowitz","year":"2018","unstructured":"Ezekowitz MD, Pollack CV Jr, Halperin JL, et al. Apixaban compared to heparin\/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39(32):2959\u201371.","journal-title":"Eur Heart J"},{"key":"7078_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11239-017-1599-5","volume":"45","author":"V Russo","year":"2017","unstructured":"Russo V, Rago A, Papa AA, D\u2019Onofrio A, Golino P, Nigro G. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. J Thromb Thrombolysis. 2017;45:206\u201312.","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"7078_CR12","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1093\/europace\/eux127","volume":"20","author":"AJ Camm","year":"2018","unstructured":"Camm AJ, Turpie AGG, Hess S, et al. XANTUS Investigators. Outcomes after catheter ablation and cardioversion in patients with non-valvulara trial fibrillation: results from the prospective, observational XANTUS study. Europace. 2018;20(6):e87\u201395.","journal-title":"Europace"},{"issue":"4","key":"7078_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40256-019-00341-9","volume":"19","author":"A Rago","year":"2019","unstructured":"Rago A, Papa AA, Cassese A, Arena G, Magliocca MCG, D\u2019Onofrio A, et al. Clinical performance of apixaban vs. vitamin K antagonists in patients with atrial fibrillation undergoing direct electrical current cardioversion: a prospective propensity score-matched cohort study. Am J Cardiovasc Drugs. 2019;19(4):421\u20137.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"38","key":"7078_CR14","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893\u2013962.","journal-title":"Eur Heart J"},{"key":"7078_CR15","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. ISSN 0195-668X. 2018;39:1330\u201393.","journal-title":"Eur Heart J"},{"issue":"10055","key":"7078_CR16","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","volume":"388","author":"A Goette","year":"2016","unstructured":"Goette A, Merino JL, Ezekowitz MD, ENSURE-AF investigators, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995\u20132003 Erratum in: Lancet. 2016 Oct 22;388(10055):1984.","journal-title":"Lancet"},{"issue":"11","key":"7078_CR17","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, the Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015 Nov;13(11):2119\u20132.","journal-title":"J Thromb Haemost"},{"key":"7078_CR18","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/medicina55100660","volume":"55","author":"G Coppola","year":"2019","unstructured":"Coppola G, Manno G, Mignano A, et al. Management of direct oral anticoagulants in patients with atrial fibrillation undergoing cardioversion. Medicina. 2019;55:660.","journal-title":"Medicina"},{"key":"7078_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ijcard.2015.02.075","volume":"184","author":"G Stabile","year":"2015","unstructured":"Stabile G, Russo V, Rapacciuolo A, de Divitiis M, de Simone A, Solimene F, et al. Transesophageal echocardiograpy in patients with persistent atrial fibrillation undergoing electrical cardioversion on new oral anticoagulants: a multi center registry. Int J Cardiol. 2015;184:283\u20134.","journal-title":"Int J Cardiol"},{"key":"7078_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2017.07.048","volume":"249","author":"E Bertaglia","year":"2017","unstructured":"Bertaglia E, Anselmino M, Zorzi A, Russo V, Toso E, Peruzza F, et al. NOACs and atrial fibrillation: incidence and predictors of left atrial thrombus in the real world. Int J Cardiol. 2017;249:179\u201383.","journal-title":"Int J Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07078-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07078-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07078-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T05:18:27Z","timestamp":1632115107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07078-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["7078"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07078-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"10 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}